QIAD Stock Overview
Offers sample to insight solutions that transform biological materials into molecular insights. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Qiagen N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$40.95 |
| 52 Week High | US$42.31 |
| 52 Week Low | US$37.07 |
| Beta | 0.40 |
| 11 Month Change | 3.94% |
| 3 Month Change | n/a |
| 1 Year Change | 9.29% |
| 33 Year Change | -21.57% |
| 5 Year Change | 1.97% |
| Change since IPO | 196.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| QIAD | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -0.4% | -2.8% | 2.2% |
| 1Y | 9.3% | -29.3% | 8.0% |
Return vs Industry: QIAD exceeded the UK Life Sciences industry which returned -30.2% over the past year.
Return vs Market: QIAD exceeded the UK Market which returned 6.6% over the past year.
Price Volatility
| QIAD volatility | |
|---|---|
| QIAD Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: QIAD's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine QIAD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 5,800 | Thierry Bernard | www.qiagen.com |
Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.
Qiagen N.V. Fundamentals Summary
| QIAD fundamental statistics | |
|---|---|
| Market cap | €9.05b |
| Earnings (TTM) | €89.40m |
| Revenue (TTM) | €1.89b |
101.2x
P/E Ratio4.8x
P/S RatioIs QIAD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QIAD income statement (TTM) | |
|---|---|
| Revenue | US$1.97b |
| Cost of Revenue | US$663.20m |
| Gross Profit | US$1.30b |
| Other Expenses | US$1.21b |
| Earnings | US$92.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.42 |
| Gross Margin | 66.27% |
| Net Profit Margin | 4.73% |
| Debt/Equity Ratio | 57.0% |
How did QIAD perform over the long term?
See historical performance and comparison